Skip to main content
SpringerLink
Log in

Islet and Pancreas Transplantation

  • Chapter
  • First Online:
Immunoendocrinology: Scientific and Clinical Aspects

Part of the book series: Contemporary Endocrinology ((COE))

  • 867 Accesses

Summary

Transplantation of whole pancreas or of purified pancreatic islets can restore insulin secretion in patients with insulin-dependent, type 1 diabetes (T1D). Both procedures reverse diabetes in most patients, improving chronic complications and quality of life, but require chronic, systemic immunosuppression. Given the side effects and health risks associated with immunosuppression, exogenous insulin therapy remains the mainstay of treatment for most patients with T1D, unless patients cannot adequately control their metabolism with exogenous insulin or develop life-threatening complications (such as severe hypoglycemia and kidney failure) that can be corrected by transplantation. While pancreas transplantation is presently associated with longer graft survival and function than islet transplantation, it requires invasive surgery compared to the less invasive islet infusion procedure and has a higher risk of perioperative mortality and morbidity. Thus, clinical indications and patient selection criteria for the two procedures are different. Islet transplants are mostly performed in patients with brittle diabetes and severe hypoglycemia. Patients with end stage renal disease are candidates for simultaneous-kidney pancreas transplantation, which accounts for the majority of pancreas transplants. This chapter will review the current status of both islet and pancreas transplantation and discuss major challenges and future directions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ryan EA, Bigam D, Shapiro AM. Current indications for pancreas or islet transplant. Diabetes Obes Metab 2006;8(1):1–7.

    Article  PubMed  Google Scholar 

  2. Leitao CB, Cure P, Tharavanij T, Baidal DA, Alejandro R. Current challenges in islet transplantation. Curr Diab Rep 2008;8(4):324–331.

    Article  PubMed  Google Scholar 

  3. Ricordi C, Lacy PE, Finke EH. Automated method for isolation of human pancreatic islets. Diabetes 1988;37:413–420.

    Article  PubMed  CAS  Google Scholar 

  4. Antonioli B, Fermo I, Cainarca S, et al. Characterization of collagenase blend enzymes for human islet transplantation. Transplantation 2007;84(12):1568–1575.

    Article  PubMed  CAS  Google Scholar 

  5. Ichii H, Wang X, Messinger S, et al. Improved human islet isolation using nicotinamide. Am J Transplant 2006;6(9):2060–2068.

    Article  PubMed  CAS  Google Scholar 

  6. Ichii H, Sakuma Y, Pileggi A, et al. Shipment of human islets for transplantation. Am J Transplant 2007;7(4):1010–1020.

    Article  PubMed  CAS  Google Scholar 

  7. Ichii H, Inverardi L, Pileggi A, et al. A novel method for the assessment of cellular composition and beta-cell viability in human islet preparations. Am J Transplant 2005;5(7):1635–1645.

    Article  PubMed  Google Scholar 

  8. Baidal DA, Froud T, Ferreira JV, Khan A, Alejandro R, Ricordi C. The bag method for islet cell infusion. Cell Transplant 2003;12(7):809–813.

    PubMed  Google Scholar 

  9. Goss JA, Soltes G, Goodpastor SE, et al. Pancreatic islet transplantation: the radiographic approach. Transplantation 2003;76(1):199–203.

    Article  PubMed  Google Scholar 

  10. Bretzel RG, Brandhorst D, Brandhorst H, et al. Improved survival of intraportal pancreatic islet cell allografts in patients with type-1 diabetes mellitus by refined peritransplant management. J Mol Med 1999;77(1):140–143.

    Article  PubMed  CAS  Google Scholar 

  11. Mineo D, Sageshima J, Burke GW, Ricordi C. Minimization and withdrawal of steroids in pancreas and islet transplantation. Transpl Int 2009;22(1):20–37.

    Article  PubMed  Google Scholar 

  12. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343(4):230–238.

    Article  PubMed  CAS  Google Scholar 

  13. Ryan EA, Lakey JR, Paty BW, et al. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 2002;51(7):2148–2157.

    Article  PubMed  CAS  Google Scholar 

  14. Alejandro R, Barton FB, Hering BJ, Wease S. 2008 Update from the Collaborative Islet Transplant Registry. Transplantation 2008;86(12):1783–1788.

    Article  PubMed  Google Scholar 

  15. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006;355(13):1318–1330.

    Article  PubMed  CAS  Google Scholar 

  16. Monti P, Scirpoli M, Maffi P, et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest 2008;118(5):1806–1814.

    PubMed  CAS  Google Scholar 

  17. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007;117(9):2553–2561.

    Article  PubMed  CAS  Google Scholar 

  18. Leitao CB, Tharavanij T, Cure P, et al. Restora­tion of hypoglycemia awareness after islet transplantation. Diabetes Care 2008;31(11):2113–2115.

    Article  PubMed  Google Scholar 

  19. Tharavanij T, Betancourt A, Messinger S, et al. Improved long-term health-related quality of life after islet transplantation. Transplantation 2008;86(9):1161–1167.

    Article  PubMed  Google Scholar 

  20. Luzi L, Perseghin G, Brendel MD, et al. Metabolic effects of restoring partial beta-cell function after islet allotransplantation in type 1 diabetic patients. Diabetes 2001;50(2):277–282.

    Article  PubMed  CAS  Google Scholar 

  21. Paty BW, Ryan EA, Shapiro AM, Lakey JR, Robertson RP. Intrahepatic islet transplantation in type 1 diabetic patients does not restore hypoglycemic hormonal counterregulation or symptom recognition after insulin independence. Diabetes 2002;51(12):3428–3434.

    Article  PubMed  CAS  Google Scholar 

  22. Rickels MR, Schutta MH, Mueller R, et al. Glycemic thresholds for activation of counterregulatory hormone and symptom responses in islet transplant recipients. J Clin Endocrinol Metab 2007;92(3):873–879.

    Article  PubMed  CAS  Google Scholar 

  23. Rickels MR, Schutta MH, Markmann JF, Barker CF, Naji A, Teff KL. {beta}-Cell function following human islet transplantation for type 1 diabetes. Diabetes 2005;54(1):100–106.

    Article  PubMed  CAS  Google Scholar 

  24. Rickels MR, Schutta MH, Mueller R, et al. Islet cell hormonal responses to hypoglycemia after human islet transplantation for type 1 diabetes. Diabetes 2005;54(11):3205–3211.

    Article  PubMed  CAS  Google Scholar 

  25. Ghofaili KA, Fung M, Ao Z, et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 2007;83(1):24–28.

    Article  PubMed  Google Scholar 

  26. Froud T, Faradji RN, Pileggi A, et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation 2008;86(1):36–45.

    Article  PubMed  Google Scholar 

  27. Gangemi A, Salehi P, Hatipoglu B, et al. Islet transplantation for brittle type 1 diabetes: the UIC protocol. Am J Transplant 2008;8(6):1250–1261.

    Article  PubMed  CAS  Google Scholar 

  28. Cure P, Pileggi A, Alejandro R. Exenatide and rare adverse events. N Engl J Med 2008;358(18):1969–1970.

    Article  PubMed  CAS  Google Scholar 

  29. Ponte GM, Pileggi A, Messinger S, et al. Toward maximizing the success rates of human islet isolation: influence of donor and isolation factors. Cell Transplant 2007;16(6):595–607.

    PubMed  Google Scholar 

  30. Campbell PM, Senior PA, Salam A, et al. High risk of sensitization after failed islet transplantation. Am J Transplant 2007;7(10):2311–2317.

    Article  PubMed  CAS  Google Scholar 

  31. Cardani R, Pileggi A, Ricordi C, et al. Allosensitization of islet allograft recipients. Transplantation 2007;84(11):1413–1427.

    Article  PubMed  Google Scholar 

  32. Fung MA, Warnock GL, Ao Z, et al. The effect of medical therapy and islet cell transplantation on diabetic nephropathy: an interim report. Transplantation 2007;84(1):17–22.

    Article  PubMed  Google Scholar 

  33. Maffi P, Bertuzzi F, De TF, et al. Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy. Diabetes Care 2007;30(5):1150–1155.

    Article  PubMed  CAS  Google Scholar 

  34. Senior PA, Zeman M, Paty BW, Ryan EA, Shapiro AM. Changes in renal function after clinical islet transplantation: four-year observational study. Am J Transplant 2007;7(1):91–98.

    Article  PubMed  CAS  Google Scholar 

  35. Leitao CB, Cure P, Messinger S, et al. Stable renal function after islet transplantation: importance of patient selection and aggressive clinical management. Transplantation 2009;87(5):681–688.

    Article  PubMed  Google Scholar 

  36. Toso C, Baertschiger R, Morel P, et al. Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol. Am J Transplant 2006;6(5 Pt 1):1049–1058.

    Article  PubMed  CAS  Google Scholar 

  37. Cure P, Pileggi A, Froud T, et al. Improved metabolic control and quality of life in seven patients with type 1 diabetes following islet after kidney transplantation. Transplantation 2008;85(6):801–812.

    Article  PubMed  CAS  Google Scholar 

  38. Tan J, Yang S, Cai J, et al. Simultaneous islet and kidney transplantation in seven patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction. Diabetes 2008;57(10):2666–2671.

    Article  PubMed  CAS  Google Scholar 

  39. Gerber PA, Pavlicek V, Demartines N, et al. Simultaneous islet-kidney vs pancreas-kidney transplantation in type 1 diabetes mellitus: a 5 year single centre follow-up. Diabetologia 2008;51(1):110–119.

    Article  PubMed  CAS  Google Scholar 

  40. Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med 2000;17(3):181–189.

    Article  PubMed  CAS  Google Scholar 

  41. Hansen A, Johansson BL, Wahren J, von Bibra H. C-peptide exerts beneficial effects on myocardial blood flow and function in patients with type 1 diabetes. Diabetes 2002;51(10):3077–3082.

    Article  PubMed  CAS  Google Scholar 

  42. Del CU, Fiorina P, Amadio S, et al. Evaluation of polyneuropathy markers in type 1 diabetic kidney transplant patients and effects of islet transplantation: neurophysiological and skin biopsy longitudinal analysis. Diabetes Care 2007;30(12):3063–3069.

    Article  Google Scholar 

  43. Fiorina P, Gremizzi C, Maffi P, et al. Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients. Diabetes Care 2005;28(6):1358–1365.

    Article  PubMed  Google Scholar 

  44. Fiorina P, Venturini M, Folli F, et al. Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation. Diabetes Care 2005;28(6):1303–1310.

    Article  PubMed  Google Scholar 

  45. Fiorina P, Folli F, Maffi P, et al. Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation: a comparison between kidney-pancreas and kidney-alone transplantation. Transplantation 2003;75(8):1296–1301.

    Article  PubMed  Google Scholar 

  46. Fiorina P, Folli F, Bertuzzi F, et al. Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in type 1 diabetic kidney-transplanted patients. Diabetes Care 2003;26(4):1129–1136.

    Article  PubMed  Google Scholar 

  47. Thompson DM, Begg IS, Harris C, et al. Reduced progression of diabetic retinopathy after islet cell transplantation compared with intensive medical therapy. Transplantation 2008;85(10):1400–1405.

    Article  PubMed  Google Scholar 

  48. Warnock GL, Thompson DM, Meloche RM, et al. A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes. Transplantation 2008;86(12):1762–1766.

    Article  PubMed  Google Scholar 

  49. Sutherland DE, Gruessner AC, Carlson AM, et al. Islet autotransplant outcomes after total pancreatectomy: a contrast to islet allograft outcomes. Transplantation 2008;86(12):1799–1802.

    Article  PubMed  Google Scholar 

  50. Hering BJ, Kandaswamy R, Harmon JV, et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 2004;4(3):390–401.

    Article  PubMed  CAS  Google Scholar 

  51. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005;293(7):830–835.

    Article  PubMed  CAS  Google Scholar 

  52. Bellin MD, Kandaswamy R, Parkey J, et al. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant 2008;8(11):2463–2470.

    Article  PubMed  CAS  Google Scholar 

  53. Froud T, Baidal DA, Faradji R, et al. Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. Transplantation 2008;86(12):1695–1701.

    Article  PubMed  CAS  Google Scholar 

  54. Shapiro AMJ, Koh A, Kin T, et al. Outcomes following Alemtuzumab induction in clinical islet transplantation. Am J Transplant 2008;8(Suppl 2):S213.

    Google Scholar 

  55. Posselt A, Szot G, Frassseto L, et al. Ilset allograft survival in type 1 diabetics using a calcineurin-free based on Efalizumab and Sirolimus. Am J Transplant 2008;8(Suppl 2):S253.

    Google Scholar 

  56. Pileggi A, Molano RD, Ricordi C, et al. Reversal of diabetes by pancreatic islet transplantation into a subcutaneous, neovascularized device. Transplantation 2006;81(9):1318–1324.

    Article  PubMed  Google Scholar 

  57. Leichtman AB, Cohen D, Keith D, et al. Kidney and pancreas transplantation in the United States, 1997–2006: the HRSA Breakthrough Collaboratives and the 58 DSA Challenge. Am J Transplant 2008;8(4 Pt 2):946–957.

    Article  PubMed  CAS  Google Scholar 

  58. Burke GW, Ciancio G, Sollinger HW. Advances in pancreas transplantation. Transplantation 2004;77(9 Suppl):S62–S67.

    Article  PubMed  CAS  Google Scholar 

  59. Ciancio G, Burke GW, Miller J. Current treatment practices in immunosuppression. Expert Opin Pharmacother 2000;1:1307–1330.

    Article  PubMed  CAS  Google Scholar 

  60. Ciancio G, Mattiazzi A, Roth D, Kupin W, Miller J, Burke GW. The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants. Clin Transplant 2003;17(5):428–432.

    Article  PubMed  Google Scholar 

  61. Burke GW, Ciancio G. Critical care issues in the renal and pancreatic allograft recipient. In: Civetta JM, Taylor RW, Kirby RR, eds. Critical Care. 3rd ed. Philadelphia: J.B. Lippincott Company, 1997:1311–1315.

    Google Scholar 

  62. White SA, Shaw JA, Sutherland DE. Pancreas transplantation. Lancet 2009;373(9677):1808–1817.

    Article  PubMed  CAS  Google Scholar 

  63. Burke GW, III, Ciancio G, Figueiro J, et al. Hypercoagulable state associated with kidney-pancreas transplantation. Thromboelastogram-directed anti-coagulation and implications for future therapy. Clin Transplant 2004;18(4):423–428.

    Article  PubMed  Google Scholar 

  64. Burke GW, Ciancio G, Cirocco R, et al. Microangiopathy in kidney and simultaneous pancreas/kidney recipients treated with tacrolimus: evidence of endothelin and cytokine involvement. Transplantation 1999;68(9):1336–1342.

    Article  PubMed  CAS  Google Scholar 

  65. Burke GW, Ciancio G, Olson L, Roth D, Miller J. Ten-year survival after simultaneous pancreas/kidney transplantation with bladder drainage and tacrolimus-based immunosuppression. Transplant Proc 2001;33(1–2):1681–1683.

    Article  PubMed  CAS  Google Scholar 

  66. Stratta RJ, Shokouh-Amiri MH, Egidi MF, et al. Long-term experience with simultaneous kidney-pancreas transplantation with portal-enteric drainage and tacrolimus/mycophenolate mofetil-based immunosuppression. Clin Transplant 2003;17 Suppl 9:69–77.

    Article  PubMed  Google Scholar 

  67. Bruce DS, Sollinger HW, Humar A, et al. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. Transplantation 2001;72(10):1637–1643.

    Article  PubMed  CAS  Google Scholar 

  68. Stratta RJ, Alloway RR, Hodge E, Lo A. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis. Clin Transplant 2002;16(1):60–68.

    Article  PubMed  Google Scholar 

  69. Stratta RJ, Alloway RR, Hodge E, Lo A. A multicenter, open-label, comparative trial of two daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: 6-month interim analysis. Transplant Proc 2002;34(5):1903–1905.

    Article  PubMed  CAS  Google Scholar 

  70. Burke GW, Ciancio G, Gaynor JJ, et al. Lower rate of acute rejection with rapamycin versus mycophenolate mofetil in simultaneous kidney transplant recipients: eight year follow-up. Am J Transplant 2009;9(Suppl 2):216.

    Google Scholar 

  71. Gruessner RW, Kandaswamy R, Humar A, Gruessner AC, Sutherland DE. Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation 2005;79(9):1184–1189.

    Article  PubMed  CAS  Google Scholar 

  72. Kaufman DB, Leventhal JR, Gallon LG, Parker MA. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results. Am J Transplant 2006;6(2):331–339.

    Article  PubMed  CAS  Google Scholar 

  73. Fioretto P, Sutherland DE, Najafian B, Mauer M. Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. Kidney Int 2006;69(5):907–912.

    Article  PubMed  CAS  Google Scholar 

  74. Coppelli A, Giannarelli R, Vistoli F, et al. The beneficial effects of pancreas transplant alone on diabetic nephropathy. Diabetes Care 2005;28(6):1366–1370.

    Article  PubMed  Google Scholar 

  75. Giannarelli R, Coppelli A, Sartini MS, et al. Pancreas transplant alone has beneficial effects on retinopathy in type 1 diabetic patients. Diabetologia 2006;49(12):2977–2982.

    Article  PubMed  CAS  Google Scholar 

  76. Pearce IA, Ilango B, Sells RA, Wong D. Stabilisation of diabetic retinopathy following simultaneous pancreas and kidney transplant. Br J Ophthalmol 2000;84(7):736–740.

    Article  PubMed  CAS  Google Scholar 

  77. Hathaway DK, Hartwig MS, Milstead J, Elmer D, Evans S, Gaber AO. Improvement in quality of life reported by diabetic recipients of kidney-only and pancreas-kidney allografts. Transplant Proc 1994;26(2):512–514.

    PubMed  CAS  Google Scholar 

  78. Navarro X, Sutherland DE, Kennedy WR. Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol 1997;42(5):727–736.

    Article  PubMed  CAS  Google Scholar 

  79. Laughlin E, Burke G, Pugliese A, Falk B, Nepom G. Recurrence of autoreactive antigen-specific CD4+ T cells in autoimmune diabetes after pancreas transplantation. Clin Immunol 2008;128(1):23–30.

    Article  PubMed  CAS  Google Scholar 

  80. Diamantopoulos S, Allende G, Martin-Pagola A, et al. Recurrence of type 1 diabetes (T1DR) after simultaneous pancreas-kidney (SPK) transplantation is associated with islet cell autoantibody conversion. Acta Diabetol 2007;44(S1):S13.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgery, Division of Transplantation, Jackson Memorial Hospital, University of Miami Hospital, Miami, FL, USA

    Gaetano Ciancio & George W. Burke

  2. Miller School of Medicine, Diabetes Research Institute, University of Miami, Miami, FL, USA

    Alberto Pugliese

  3. Diabetes Research Institute, University of Miami, Miami, FL, USA

    Camillo Ricordi

Authors
  1. Gaetano Ciancio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alberto Pugliese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. George W. Burke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Camillo Ricordi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Health Sciences Center, Children's Hospital, University of Colorado, East 9th Avenue 4200, Denver, 80262, Colorado, USA

    George S. Eisenbarth

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Ciancio, G., Pugliese, A., Burke, G.W., Ricordi, C. (2009). Islet and Pancreas Transplantation. In: Eisenbarth, G. (eds) Immunoendocrinology: Scientific and Clinical Aspects. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-478-4_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-478-4_23

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60327-477-7

  • Online ISBN: 978-1-60327-478-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation